AMLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amylyx Pharmaceuticals Inc (AMLX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has positive analyst sentiment and potential catalysts, the financial performance is weak, insider selling is significant, and there are no strong proprietary trading signals. Considering the user's impatience and unwillingness to wait for optimal entry points, holding off on this stock is advisable until clearer positive financial trends or stronger signals emerge.
The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 17.663), which may limit immediate upside potential.
Analysts are highly optimistic about the Phase 3 LUCIDITY trial for avexitide, with raised price targets and high confidence in FDA approval. The drug addresses a significant unmet medical need, which could be a large market opportunity.
Insider selling has increased significantly (2291.45% over the last month), raising concerns about management's confidence. Additionally, legal investigations into fiduciary breaches could create uncertainty. Financial performance is weak, with declining net income, EPS, and gross margin.
The company's Q4 2025 financials show no revenue growth (0% YoY), a net income drop of -12.11% YoY, EPS down -45.45% YoY, and gross margin down -100%. These metrics indicate poor financial health and lack of profitability.
Analysts maintain a Buy rating with raised price targets (ranging from $19 to $34). They express strong confidence in the success of the LUCIDITY trial and the potential approval of avexitide, which could address a significant unmet need in post-bariatric hypoglycemia.
